title: Nucleotide analogs as novel anti-hepatitis B virus agents.
abstract: During the past decade, nucleotide analogs have emerged as novel antiviral agents against hepatitis B virus. Adefovir dipivoxil, a prototype phosphonate analog, has been approved for chronic hepatitis B virus therapy, and additional phosphonate analogs and di- and tri-nucleotides are under development. Several innovative prodrug derivatizations have also been reported to improve the oral bioavailability of nucleotide analogs, which usually carry a negative charge.
authors.affiliation: Spring Bank Technologies Inc, Milford, MA 01757, USA. kiyer@springbanktech.com
authors.forename: Radhakrishnan P
authors.initials: RP
authors.lastname: Iyer
authors.forename: Seetharamaiyer
authors.initials: S
authors.lastname: Padmanabhan
authors.forename: Guangrong
authors.initials: G
authors.lastname: Zhang
authors.forename: John D
authors.initials: JD
authors.lastname: Morrey
authors.forename: Brent E
authors.initials: BE
authors.lastname: Korba
mesh_terms: D000998:Antiviral Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D009711:Nucleotides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D011355:Prodrugs / Q000737:chemistry / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D009711:Nucleotides; D011355:Prodrugs